Education case: a case-based approach to overlap syndromes in autoimmune liver disease in patient with ulcerative colitis
Gastroenterology and Hepatology from Bed to Bench,
Simultaneous occurrence of immune-based gastrointestinal diseases and autoimmune hepatitis, although not common, is of clinical importance. Some clinical and laboratory findings such as severe pruritus and elevated alkaline phosphatase raise suspicion of a biliary disease which overlaps autoimmune hepatitis. A strong clinical suspicion of overlap syndrome in a patient with autoimmune hepatitis prompts more diagnostic evaluations like MRCP, liver biopsy, and secondary laboratory tests. Patients who fall into the category of overlap syndrome proceed with timely monitoring of known complications including colorectal carcinomas, cholangiocarcinomas, and gallbladder cancers. It is strongly recommended that all simultaneous immune-based involvements be searched prior to labeling a patient as having pure autoimmune hepatitis.
The current study attempted to express all challenges about a case with overlap syndrome referred to the gastroenterology ward of Taleghani Hospital and to review the latest articles and related guidelines about the diagnosis, treatment, complications, and surveillance of the mentioned patient with autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and inflammatory bowel disease (IBD).
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, Ulcerative Colitis, overlap syndrome.
How to Cite
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35.
Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67:6-19.
Lala V, Goyal A, Minter DA. Liver function tests. InStatPearls [Internet] 2021 Aug 20. StatPearls Publishing.
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology 2020;72:671-722.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015;63:971-1004.
Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:1611-29.
Canh HN, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, et al. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. J Clin Pathol 2017;70:961-969.
Björnsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011;9:57-63.
Yeoman AD, Westbrook RH, Al‐Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplied International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50:538-45.
Pape S, Gevers TJ, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, et al. Predniso(lo)ne Dosage and Chance of Remission in Patients with Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019;17:2068-2075.
Hübener S, Oo YH, Than NN, Hübener P, Weiler-Normann C, Lohse AW, et al. Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. Clin Gastroenterol Hepatol 2016;14:445-53.
Beretta-Piccoli BT, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017;23:6030-6048.
Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2021;22:1475-88.
Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: A current literature review. Clin Mol Hepatol 2017;23:22-26.
Paiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients with Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018;16:260-7.
Dhaliwal HK, Hoeroldt BS, Dube AK, McFarlane E, Underwood JC, Karajeh MA, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 2015;110:993-9.
Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980-9.
Gossard AA, Lindor KD. Autoimmune hepatitis: a review. J Gastroenterol 2012;47:498-503.
Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology 2013;57:2399-406.
Li Y, Yan L, Wang R, Wang Q, You Z, Li B, et al. Serum Immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis Type 1: a single-center experience and literature review. Clin Rev Allergy Immunol 2022;62:292-300.
Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol 2018;68:754-63.
Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute severe autoimmune hepatitis: Corticosteroids or liver transplantation? Liver Transpl 2019;25:946-59.
Martin P, DiMartini A, Feng S, Brown Jr R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American association for the study of liver diseases and the American society of transplantation. Hepatology 2014;59:1144-65.
Nayagam JS, Miquel R, Joshi D. Overlap syndrome with autoimmune hepatitis and primary sclerosing cholangitis. EMJ Hepatol 2019;7:95–104.
Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009;50:528-37.
To Y, Silveira M. Overlap syndrome of autoimmune hepatitis and primary biliary sclerosis. Clin Liver Dis 2018;22:603-611.
Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol 2015;13:2088-108.
Lindor KD, Kowdley KV, Harrison ME, American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015;110:646-59.
Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol 2018;53:1006-1034.
Björnsson ES, Kalaitzakis E. Recent advances in the treatment of primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 2021;15:413-25.
Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
Bowlus CL, Lim JK, Lindor KD. aga clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: Expert review. Clin Gastroenterol Hepatol 2019;17:2416-2422.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723-50.
Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: A long‐term single‐centre study. Liver Int 2012;32:214-22.
Pai RK, Jairath V, Casteele NV, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2018;88:887-898.
Ozaki R, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis 2018;12:1288-1294.
Chrisinger JA, Dassopoulos T, Yan Y, Nalbantoglu. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World J Gastroenterol 2020;26:4126-4139.
Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC Phenotypes of PSC-IBD. Curr Gastroenterol Rep 2018;20:1-3.
Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, et al. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J gastroenterol Hepatol 2017;29:91-97.
Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut liver 2018;12:17-29.
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384-413.
Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 2019;156:748-64.
Karnsund S, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol 2020;26:5362-5374.
Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: Who to treat with what agent? Nat Rev Rheumatol 2015;11:98-109.
Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: Preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241-258.
Lo B, Holm JP, Vester-Andersen MK, Bendtsen F, Vind I, Burisch J. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: A Danish population-based inception cohort with 10 years of follow-up. J Crohns Colitis 2020;14:904-914.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:44-100.
Kim DK, Hunter P. Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule, United States, 2019. Ann Intern Med 2019;170:182-92.
Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015;81:1101-21.
Baars JE, Kuipers EJ, Van Haastert M, Nicolaï JJ, Poen AC, Van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol 2012;47:1308-22.
Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, et al. European evidence-based consensus: Inflammatory bowel disease and malignancies. J Crohns Colitis 2015;9:945-65.
Ricci C, Scaldaferri F, Colombo F, Armuzzi A, Lopetuso LR, Leone S, et al. Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience. Eur Rev Med Pharmacol Sci 2020;24:564-570.
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86.
Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847-58.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times